病毒載體和質體DNA生產市場規模、佔有率和成長分析：按產品類型、工作流程、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球病毒載體和質體DNA 生產市場價值為 63 億美元，預計到 2025 年將成長至 71.6 億美元，到 2033 年將成長至 200.1 億美元，預測期（2026-2033 年）複合年成長率為 13.7%。

全球病毒載體和質體DNA生產市場的主要驅動力是先進治療方法和疫苗平台的激增，這些平台需要可擴展的、符合GMP標準的生技藥品。該市場涵蓋合約研發生產機構（CDMO）和內部生產設施，這些機構生產AAV、慢病毒和腺病毒載體，以及用於基因治療和核酸疫苗的質體DNA。可靠的供應和穩定的品質是成功治療的關鍵，隨著臨床需求超過現有產能，申辦方擴大將製造地給專業的CDMO。隨著投資轉向一次性生物反應器和高產發酵系統，人工智慧技術被引入以提高產量、簡化流程並促進即時分析，從而支持小規模研究批次向穩健的臨床和商業化生產的過渡。

全球病毒載體和質體DNA生產市場按產品類型、工作流程、應用、最終用戶和地區進行細分。依產品類型分類，市場分為「病毒載體」和「質體DNA」。依工作流程分類，市場分為「上游工程」、「下游製程」、「填充和精製服務」以及「分析和品質檢測」。依應用分類，市場分為細胞和基因治療、疫苗、腫瘤、感染疾病、罕見疾病、科研應用及其他。依最終用戶分類，市場分為生物製藥公司、合約研發生產機構（CDMO）、研究機構、學術機構及其他。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球病毒載體和質體DNA生產市場的成長要素

隨著基因治療研究的活性化，對高品質病毒載體和質體DNA的需求顯著成長，這需要可擴展的生產能力和專業知識。為了滿足不斷變化的治療需求，研發人員致力於開發更永續、更精準的治療方法，生物製藥公司和契約製造正加大對製程最佳化、載體改進和供應鏈強化的投資。這種持續的需求提高了生產商的收入可預測性，並在許多情況下促使他們擴大專用設施。此外，技術轉移合作的興起正在加速市場發展，並促進創新生物製藥解決方案的應用，即使在充滿挑戰的環境下也是如此。

全球病毒載體和質體DNA生產市場的限制因素

全球病毒載體和質體DNA生產市場面臨許多挑戰，其中最主要的挑戰在於不斷變化且日益嚴格的監管要求，這些要求會延長研發週期、造成不確定性並阻礙市場成長。企業必須遵守各地不同的品質、安全和環境標準法規，這導致需要大量的文件工作和合規方面的專業知識。這種複雜性可能會阻礙新進入者，並減緩產能擴張。此外，即使科學進展顯著，且各種措施都展現出商業性熱情，與法規核准相關的資源需求增加也會阻礙生產基礎設施和供應鏈的快速擴張。

病毒載體和質體DNA生產市場的全球趨勢

全球病毒載體和質體DNA生產市場正經歷著向模組化和靈活化生產系統的顯著轉變，這種轉變使得生產線能夠快速重新配置，以適應不同的工作流程。這一趨勢透過利用標準化的模組化平台，加速了技術轉移並簡化了產品上市流程，這些平台能夠促進並行處理並最大限度地降低污染風險。此外，由此產生的去中心化生產策略降低了資本投資風險，從而鼓勵了更多投資。特別是中小型生物技術公司，現在無需承擔長期基礎設施投資的負擔，即可獲得先進的GMP生產能力，從而提高了市場創新能力和應對力。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球病毒載體與質體DNA生產市場規模：依產品類型分類

• 病毒載體
  • 腺結合病毒（AAV）載體
  • 慢病毒載體
  • 逆轉錄病毒載體
  • 腺病毒載體
  • 其他
• 質體DNA
  • 用於研究的質體DNA
  • GMP級質體DNA
  • 其他

全球病毒載體與質體DNA生產市場規模：依工作流程分類

• 上游工程
• 下游加工
• 灌裝和精加工服務
• 分析和品質測試

全球病毒載體和質體DNA製造市場規模：按應用領域分類。

• 細胞和基因治療
• 疫苗
• 腫瘤學
• 感染疾病
• 罕見疾病
• 出於研究目的
• 其他

全球病毒載體與質體DNA生產市場規模：依最終用戶分類

• 生物製藥公司
• 合約研發生產組織（CDMO）
• 研究機構
• 學術機構
• 其他

全球病毒載體和質體DNA生產市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Catalent, Inc.
• Lonza Group AG
• FUJIFILM Holdings Corporation
• Charles River Laboratories International, Inc.
• Merck KGaA
• Sartorius AG
• Aldevron LLC
• Cobra Biologics Limited
• Waisman Biomanufacturing
• VGXI, Inc.
• PlasmidFactory GmbH & Co. KG
• Kaneka Eurogentec SA
• Ori Biotech Ltd.
• AGC Biologics
• Oxford Biomedica plc
• Yposkesi SAS
• Genezen Laboratories, Inc.
• BioNTech SE

結論與建議

Global Viral Vectors And Plasmid Dna Manufacturing Market size was valued at USD 6.3 Billion in 2024 and is poised to grow from USD 7.16 Billion in 2025 to USD 20.01 Billion by 2033, growing at a CAGR of 13.7% during the forecast period (2026-2033).

The global market for viral vectors and plasmid DNA manufacturing is primarily driven by the surge in advanced therapies and vaccine platforms requiring scalable GMP-grade biologics. This market encompasses both contract development and manufacturing organizations (CDMOs) and internal sites producing AAV, lentiviral, and adenoviral vectors, along with plasmid DNA for gene therapies and nucleic acid vaccines. Reliable supply and consistent quality are crucial for successful treatment outcomes, prompting sponsors to outsource production to specialized CDMOs as clinical demands outpace existing capabilities. As investment shifts toward single-use bioreactors and high-yield fermentation systems, AI technologies are being integrated to enhance yield, streamline processes, and facilitate real-time analytics, thus supporting the transition from small research batches to robust clinical and commercial production.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Viral Vectors And Plasmid Dna Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Viral Vectors And Plasmid Dna Manufacturing Market Segments Analysis

The global viral vectors and plasmid dna manufacturing market is segmented by product type, workflow, application, end user and region. Based on product type, the market is segmented into Viral Vectors and Plasmid DNA. Based on workflow, the market is segmented into Upstream Manufacturing, Downstream Processing, Fill-Finish Services and Analytical & Quality Testing. Based on application, the market is segmented into Cell & Gene Therapy, Vaccines, Oncology, Infectious Diseases, Rare Diseases, Research Applications and Others. Based on end user, the market is segmented into Biopharmaceutical Companies, Contract Development & Manufacturing Organizations (CDMOs), Research Institutes, Academic Institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Viral Vectors And Plasmid Dna Manufacturing Market

The increasing pursuit of gene therapies is driving a significant demand for high-quality viral vectors and plasmid DNA, necessitating scalable manufacturing capabilities and specialized expertise. As developers focus on creating more durable and precise treatments, biopharma companies and contract manufacturers are investing in process optimization, vector enhancement, and strengthening their supply chains to adapt to evolving therapeutic needs. This sustained demand provides manufacturers with greater revenue predictability, often leading to the expansion of dedicated facilities. Additionally, the emergence of technology transfer collaborations accelerates market progress, facilitating the adoption of innovative biologic solutions, even amidst challenging requirements.

Restraints in the Global Viral Vectors And Plasmid Dna Manufacturing Market

The Global Viral Vectors and Plasmid DNA Manufacturing market faces significant challenges due to evolving and stringent regulatory requirements that can prolong development timelines and create uncertainty, inhibiting market growth. Companies must navigate diverse regional regulations concerning quality, safety, and environmental standards, resulting in extensive documentation and a need for specialized compliance expertise. This complexity can deter new entrants into the market and delay the scaling of production capacity. Furthermore, the increased resource demands associated with regulatory approvals can hamper the rapid expansion of production infrastructure and supply chains, even when there is strong scientific progress and commercial enthusiasm for various initiatives.

Market Trends of the Global Viral Vectors And Plasmid Dna Manufacturing Market

The Global Viral Vectors and Plasmid DNA Manufacturing market is witnessing a significant trend toward modular flexible manufacturing systems that enable rapid reconfiguration of production lines for a variety of workflows. This shift fosters accelerated technology transfer and streamlined product launches while utilizing standardized modular platforms that facilitate parallel processing and minimize contamination risks. Furthermore, the decentralized manufacturing strategies emerging from this trend encourage increased investment, as they reduce capital expenditure risks. Smaller biotechnology companies are particularly benefiting, gaining access to advanced GMP production capabilities without the burden of long-term infrastructure commitments, which ultimately enhances innovation and responsiveness in the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Viral Vectors And Plasmid DNA Manufacturing Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Viral Vectors
  • Adeno-Associated Virus (AAV) Vectors
  • Lentiviral Vectors
  • Retroviral Vectors
  • Adenoviral Vectors
  • Others
• Plasmid DNA
  • Research Grade Plasmid DNA
  • GMP Grade Plasmid DNA
  • Others

Global Viral Vectors And Plasmid DNA Manufacturing Market Size by Workflow & CAGR (2026-2033)

• Market Overview
• Upstream Manufacturing
• Downstream Processing
• Fill-Finish Services
• Analytical & Quality Testing

Global Viral Vectors And Plasmid DNA Manufacturing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Cell & Gene Therapy
• Vaccines
• Oncology
• Infectious Diseases
• Rare Diseases
• Research Applications
• Others

Global Viral Vectors And Plasmid DNA Manufacturing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Biopharmaceutical Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Research Institutes
• Academic Institutions
• Others

Global Viral Vectors And Plasmid DNA Manufacturing Market Size & CAGR (2026-2033)

• North America (Product Type, Workflow, Application, End User)
  • US
  • Canada
• Europe (Product Type, Workflow, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Workflow, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Workflow, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Workflow, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Holdings Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aldevron LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cobra Biologics Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Waisman Biomanufacturing
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VGXI, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PlasmidFactory GmbH & Co. KG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaneka Eurogentec S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ori Biotech Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Biomedica plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yposkesi SAS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genezen Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations